European regional goals for hepatitis B and C elimination

Antons Mozalevskis, MD
WHO Regional Office for Europe

VHPB meeting
5th June 2015, London
Burden of viral hepatitis in the WHO European Region

- Estimated number of people living with infection\(^1\):
  - Hepatitis B - 13.3 million
  - Hepatitis C - 14 million
  - Over 60% infected live in eastern European and central Asian countries (EECA)

- Estimated number of deaths due to viral hepatitis\(^2\):
  - 60 000 deaths due to Hep B annually
  - 84 000 deaths due to Hep C annually

\(^1\) V.D. Hope et al. Epidemiol. Infect (2013) 1-17
\(^2\) Global Disease Burden Estimate
Estimated HBsAg prevalence in general adult population (WHO-EURO, 2012)
Estimated Anti-HCV prevalence in general adult population (WHO-EURO, 2012¹)

¹ V.D. Hope et al. Epidemiol. Infect (2013) 1-17
Hepatitis B and C among “most affected population groups” in the WHO European Region, 2012

GHSS for Viral Hepatitis, 2016–2021
European Regional Consultation

- June 23–26, 2015, Copenhagen
- Focal points from all European countries with focus on eastern European and central Asian countries
- Experts and partner organisations
- Civil society representatives
- A separate session for civil society to establish the Regional CS Reference Group
Regional Hepatitis Action Plan for Europe?

• The Global Health Sector Strategy (GHSS) on viral Hepatitis will be presented to the WHO Regional Committee for Europe (RC) in Vilnius, September 2015

• Comments/discussion on GHSS and its implementation in the European context

• 2016...?
Global Health Sector Strategy for viral hepatitis

• The vision
  – *A world where viral hepatitis transmission is stopped and everyone living with hepatitis has access to safe, affordable and effective care and treatment*

• The goal
  – **Eliminate viral hepatitis as a major public health problem**
## Draft global targets for 2030

<table>
<thead>
<tr>
<th>Focus</th>
<th>Indicator</th>
<th>Target (reduction from 2010 baseline)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact</td>
<td>Incidence</td>
<td>90% reduction</td>
</tr>
<tr>
<td></td>
<td>Incidence of Hepatitis B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Incidence of Hepatitis C</td>
<td>70% reduction by 2030</td>
</tr>
<tr>
<td>Impact</td>
<td>Mortality</td>
<td>60% reduction by 2030</td>
</tr>
<tr>
<td></td>
<td>Deaths due to Hepatitis B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deaths due to Hepatitis C</td>
<td></td>
</tr>
<tr>
<td>HBV</td>
<td>Coverage</td>
<td>90% +</td>
</tr>
<tr>
<td></td>
<td>Infant vaccination</td>
<td>80%</td>
</tr>
<tr>
<td></td>
<td>Birth dose vaccine (mother to child transmission)</td>
<td>90, 90, 90</td>
</tr>
<tr>
<td></td>
<td>Hepatitis B treatment (cascade)</td>
<td></td>
</tr>
<tr>
<td>HCV</td>
<td>Coverage</td>
<td>75%</td>
</tr>
<tr>
<td></td>
<td>Risk of medical exposure (in and outside facility)</td>
<td>50%</td>
</tr>
<tr>
<td></td>
<td>Harm reduction</td>
<td>90, 90, 90</td>
</tr>
<tr>
<td></td>
<td>Hepatitis C treatment (cascade to cure)</td>
<td></td>
</tr>
</tbody>
</table>
European targets for viral hepatitis?

• Aligned with the Global Targets set in the GHSS
• Will be discussed at the Regional Consultation, June 23–26 2015
• Covering targets on:
  – New infections
  – Mortality
  – Hepatitis B vaccination
  – Hepatitis B and C diagnosis and treatment
  – Other interventions
European regional context I

• Policy and coordination
  – Many countries lack National Strategies
  – Health Systems – different capacities

• Surveillance
  – Enhanced hepatitis surveillance in EU/EEA only (ECDC)
  – Very limited information on disease burden and outcomes
European regional context II

• Prevention (hepatitis B vaccination)
  – 26 MS – universal newborn vaccination
  – 21 MS – infant or child vaccination
  – 6 MS – no routine vaccination

• Prevention (hepatitis B and C)
  – Achievements and challenges in blood safety and safe medical (and not only) practices
  – Unequal access to harm reduction
European regional context III

- Care and treatment
  - Poor screening coverage
  - Scarce information on treatment coverage/cascades
  - Unequal access to treatment, and treatment largely unaffordable
WHO Regional Office for Europe

• Contact:
  – Antons Mozalevskis, WHO-EURO focal point for viral hepatitis: antons.mozaleskis@regionh.dk
  – Martin Donoghoe, WHO-EURO regional advisor on HIV/AIDS & hepatitis: mdo@euro.who.int
Thank you